Recent clinical trials have led to the approval of use of targeted therapies including pralsetinib and selpercatinib for RET-fusion positive advanced NSCLC, thus these serve as first-line treatment options for the select LCNS patients with low TMB and lack structural modifications but harbor RET fusion [104, 105]. Here, RET is linked to non-small cell lung carcinoma.